Sight Sciences, Inc. (NASDAQ:SGHT)
| Market Cap | $565.79M+35.9% |
| Revenue (ttm) | $88.39M+16.2% |
| Net Income | -$28.40M+38.4% |
| EPS | -$0.52+42.4% |
| Shares Out | 55.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 369,606 |
| Open | $10.70 |
| Previous Close | $10.62 |
| Day's Range | $9.97 - $10.70 |
| 52-Week Range | $3.38 - $11.60 |
| Beta | 2.40 |
| Analysts | Buy |
| Price Target | $10.50(+3.14%) |
| Earnings Date | Mar 3, 2027 |
About SGHT
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating SGHT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 3, 2027Earnings report
$SGHT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SGHT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SGHT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SGHT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SGHT Revenue by Segment
| Interventional Glaucoma | $21.05M | 82.16% |
| Interventional Dry Eye | $3.88M | 15.14% |
| Investment income | $692.00K | 2.70% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SGHT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SGHT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SGHT
| IWMiShares Russell 2000 ETF | $10.79M |
| VTIVanguard Morningstar Total Stock Market ETF | $8.35M |
| VXFVanguard Extended Market ETF | $4.21M |
| IWOiShares Russell 2000 Growth ETF | $4.00M |
| SMLFiShares U.S. Small-Cap Equity Factor ETF | $2.31M |
| VTWOVanguard Russell 2000 ETF | $2.15M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SGHT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat with guidance raise and analyst upgrade from UBS with raised price target drive bullish coverage.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.54% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.39% |
| LNGR | Global X Aging Population ETF | 0.29% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.12% |
| IWC | iShares Micro-Cap ETF | 0.11% |
| AIMS | Acuitas Small Cap Active ETF | 0.10% |
| SMLF | iShares U.S. Small-Cap Equity Factor ETF | 0.06% |
Weight is the stock’s share of each fund’s holdings.
